Gitadyl versus ibuprofen in patients with osteoarthritis: a double-blind, randomized, cross-over study of clinical efficacy and effects on platelets and PMNs.
The aim of the present study was (a) to examine the effects of Gitadyl (a natural product) on platelet aggregation, chemotaxis and oxidative burst response from polymorphonuclear leucocytes (PMNs) and (b) to compare Gitadyl with ibuprofen regarding pain in patients suffering from osteoarthritis. A total of 8 healthy volunteers were employed to determine the effects of Gitadyl on platelet aggregation. Leucocyte function was tested in vitro. Another group of 35 patients with mild to moderate osteoarthritis were employed in a double-blind crossover trial and treated with Gitadyl 3 tablets daily or ibuprofen 1200 mg daily (Ibumetin) in 2 courses of 3 weeks, respectively. Gitadyl did not interfere with platelet aggregation, in contrast to that observed during aspirin or ibuprofen therapy. Gitadyl, however, inhibited leucocyte chemotaxis and oxidative burst response from PMNs. Gitadyl and ibuprofen resulted in the same reduction of subjective (pain) symptoms. Gastrointestinal symptoms occurred more frequently in those patients treated with ibuprofen. It is suggested that Gitadyl can be a suitable alternative to NSAIDs for patients with pain from osteoarthritis who are prone to bleeding or who develop gastrointestinal (GI) symptoms from NSAIDs even at low dosage.